Actavis resolves Intuniv patent litigation with Shire
The settlement agreement also resolves outstanding litigation against legacy Watson’s abbreviated new drug application that remains pending at FDA. Actavis president and CEO Paul Bisaro said, "The launch
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.